IGF-1 LR3 · Research brief

IGF-1 LR3: Research Overview, Mechanism, and Handling

Real Peptides Research TeamEditorial

Updated September 5, 202610 min read

56 WORDS

Short answer

IGF-1 LR3 is a recombinant analog of human insulin-like growth factor 1 — an 83-amino-acid polypeptide carrying an arginine-for-glutamic-acid substitution at position 3 and a 13-residue N-terminal extension. Produced in microbial expression systems, it is used in laboratory research examining growth signaling, IGF binding protein interactions, tissue and organ growth, and metabolic regulation in preclinical models.

Key takeaways

IGF-1 LR3 (Long R3 IGF-1) is a recombinant 83-amino-acid analog of human insulin-like growth factor 1, modified with an arginine substitution at position 3 and a 13-residue N-terminal extension.
Those modifications are reported to sharply reduce binding to IGF binding proteins, which is the basis for its extended circulating activity in preclinical models compared with native IGF-1.
Published work spans fetal and neonatal growth physiology, glucose and insulin dynamics, organ growth in small-animal models, neurobiology, and recombinant expression systems — with results that are mixed rather than uniformly positive.
Laboratory handling centers on lyophilized cold storage, gentle reconstitution, aliquoting to limit freeze-thaw cycles, and protection from agitation and light.
IGF-1 LR3 is not an FDA-approved drug for any of the applications discussed here and is supplied for laboratory research use only.
Supplier evaluation rests on batch-specific third-party COAs, HPLC purity data, mass spectrometry identity confirmation, and traceable lot numbering.

What IGF-1 LR3 Is and Where It Came From

Native insulin-like growth factor 1 is a 70-amino-acid peptide hormone, structurally related to proinsulin, that mediates much of the downstream anabolic signaling attributed to growth hormone. In circulation, the overwhelming majority of native IGF-1 is bound to a family of six IGF binding proteins (IGFBPs), which regulate its half-life, tissue distribution, and receptor availability. That binding is not incidental — it is the principal brake on IGF-1 activity in vivo.

IGF-1 LR3, commonly written as Long R3 IGF-1, was engineered specifically to sidestep that brake. Two modifications distinguish it from the native molecule. First, the glutamic acid at position 3 is replaced with arginine, a change that markedly weakens IGFBP affinity. Second, a 13-amino-acid extension peptide is fused to the N-terminus, bringing the total length to 83 residues and further reducing binding protein association while improving expression yield and stability in recombinant systems.

The analog emerged from cell-culture science rather than clinical medicine. Long R3 IGF-1 became a widely adopted supplement in serum-free and low-serum mammalian cell culture media, where its resistance to IGFBPs secreted by cultured cells made it substantially more potent than native IGF-1 at equivalent concentrations. That industrial and academic use — supporting CHO cell productivity, hybridoma growth, and stem cell maintenance — remains one of its most established applications. Work published in Applied Microbiology and Biotechnology in 2023 describes recombinant expression of both IGF-1 and LR3 IGF-1 as xylanase fusion constructs in Pichia pastoris, reflecting continued interest in improving how the analog is manufactured at scale.

Reported Mechanism of Action

The mechanistic account of IGF-1 LR3 is straightforward in outline and considerably more nuanced in detail.

Receptor engagement

Like native IGF-1, the analog is understood to bind the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase. Receptor autophosphorylation recruits insulin receptor substrate proteins and Shc, initiating two principal downstream cascades: the PI3K/Akt/mTOR axis, associated in the literature with protein synthesis, cell survival, and substrate uptake; and the Ras/Raf/MAPK axis, associated with proliferation and differentiation signaling. IGF-1R shares substantial homology with the insulin receptor, and cross-reactivity at higher concentrations is a recurring theme in the metabolic literature.

The binding protein story

The defining feature of IGF-1 LR3 is not receptor affinity — reported affinity for IGF-1R is generally described as somewhat lower than native IGF-1 — but rather its reduced sequestration by IGFBPs. With less of the administered analog captured into binary and ternary complexes, a larger free fraction is available to reach receptors, and clearance dynamics differ from those of the native peptide. This is the mechanistic reason the analog behaves as a more persistent signal in culture and in animal models.

Systemic feedback

Free IGF signaling does not occur in isolation. A 1995 study in The Journal of Endocrinology reported that Long R3 IGF-I infusion in guinea pigs stimulated organ growth while simultaneously reducing plasma concentrations of IGF-I, IGF-II, and IGF binding proteins. That combination — local growth effects alongside suppression of the endogenous IGF axis — is a useful reminder that the analog perturbs a regulated system rather than simply adding to it.

What the Research Literature Examines

Published work on IGF-1 LR3 clusters into several distinct areas. Across all of them, evidence remains preliminary, and results are notably mixed.

Fetal and developmental physiology

Fetal sheep models represent one of the more active areas. A 2025 paper in the American Journal of Physiology — Endocrinology and Metabolism reported that IGF-1 LR3 did not promote growth in late-gestation growth-restricted fetal sheep, a negative finding that tempers assumptions about the analog's anabolic reach in compromised developmental contexts. Related work published in the Journal of Developmental Origins of Health and Disease in 2023 examined glucose-stimulated insulin secretion during acute IGF-1 LR3 infusion into fetal sheep and reported that the observed attenuation did not persist in isolated islets — suggesting the effect on insulin secretion may be systemic or contextual rather than intrinsic to the beta cell.

Metabolic and glucose regulation

Because of structural homology with insulin and shared downstream signaling, effects on glucose handling recur throughout the IGF literature. The fetal sheep work above is one example; broader preclinical interest concerns how IGFBP-independent signaling alters glucose disposal and endogenous hormone secretion. This remains an area where mechanism is better characterized than outcome.

Organ and tissue growth

The guinea pig infusion work cited above sits in a small-animal literature examining differential organ growth responses to IGF analogs. Notably, that study reported organ-level growth alongside reduced circulating IGF and IGFBP concentrations, illustrating that whole-body and tissue-level readouts can diverge.

Neurobiology

A 2025 study in the Journal of Alzheimer's Disease examined intranasal Long R3 IGF-1 in male 5XFAD mice and reported amyloid plaque remodeling in cerebral cortex without preservation of cognitive function. It is a representative example of how histological change and functional outcome can dissociate in rodent models, and why the field treats such findings as hypothesis-generating rather than conclusive.

Bioprocess and expression science

Separate from biology, a body of work addresses how the analog is produced — yeast and bacterial expression systems, fusion partners, refolding, and purification. The 2023 Pichia pastoris xylanase fusion work falls here. This literature matters to researchers because expression route influences the impurity profile that analytical testing is designed to detect.

Research area	Model systems reported	State of evidence
Cell culture supplementation	Mammalian cell lines, serum-free media	Most established application
Fetal and developmental growth	Fetal sheep	Preliminary; includes negative findings
Glucose and insulin dynamics	Fetal sheep, isolated islets	Early, mechanistically focused
Organ growth	Guinea pig	Limited; older literature
Neurobiology	Transgenic mouse models	Exploratory; outcomes dissociated
Recombinant expression	Yeast, bacterial systems	Active bioprocess literature

Laboratory Handling in General Terms

IGF-1 LR3 is supplied as a lyophilized powder because polypeptides of this size are considerably more stable dry than in solution. General handling principles apply broadly across recombinant growth factors.

Reconstitution practice

Standard laboratory practice calls for allowing the sealed vial to equilibrate to ambient temperature before opening, introducing diluent slowly down the vial wall rather than directly onto the lyophilized cake, and permitting the material to dissolve without vigorous shaking. Peptides of this class are sensitive to shear and to air-liquid interface stress, both of which can drive aggregation. Gentle swirling or inversion is preferred over vortexing. Some laboratories use mildly acidic diluent for initial solubilization before dilution into working buffer; the appropriate choice depends on the assay and downstream compatibility.

Storage

Lyophilized material is typically held frozen and protected from light and moisture, with short-term refrigeration acceptable for material in active use. Once in solution, stability declines meaningfully, and the standard mitigation is aliquoting into single-use volumes at the time of reconstitution so that repeated freeze-thaw cycles are avoided. Each cycle introduces opportunity for aggregation and loss of biological activity. Documenting reconstitution date, diluent, and concentration on every aliquot is basic traceability hygiene and prevents avoidable ambiguity when results are later interpreted. Detailed procedural guides sit in the supporting articles beneath this hub.

Regulatory and Research-Use Status

IGF-1 LR3 is not an FDA-approved drug for any of the applications discussed on this page. It has not been authorized as a therapeutic product, and it is not a dietary supplement. Material of this type is supplied for laboratory research use only, to qualified researchers and institutions, and is not intended for human or veterinary use, diagnostic use, or incorporation into any consumer product.

Beyond drug regulation, IGF-1 and its analogs appear on the World Anti-Doping Agency Prohibited List under the peptide hormones and growth factors category, and sporting bodies test for them. Import, possession, and distribution rules vary by jurisdiction, and researchers are responsible for confirming the requirements applicable to their institution and location. Institutional oversight — IACUC review for animal work, biosafety committee approval where relevant — applies independently of how a compound is classified commercially.

How Researchers Evaluate Supplier Quality

Because IGF-1 LR3 is a recombinant protein rather than a short synthetic peptide, its impurity profile is more complex: truncated species, misfolded isoforms, host cell protein carryover, and aggregates are all plausible. Analytical documentation is what separates a characterized reagent from an unknown.

Batch-specific third-party COA. The certificate should correspond to the exact lot in hand, be dated, and originate from an independent laboratory rather than being self-reported. A generic or undated COA reused across lots is a meaningful warning sign.
HPLC purity. Reversed-phase HPLC quantifies purity and reveals related-substance peaks. The chromatogram itself is more informative than a single headline percentage, since peak shape and impurity distribution carry information a number does not.
Mass spectrometry identity. Because the analog differs from native IGF-1 by a defined substitution and an N-terminal extension, observed mass should match the calculated mass for the 83-residue construct. Mass spec is the primary defense against substitution or mislabeling.
Batch traceability. A lot number that links vial, COA, and production record allows results to be tied to specific material — essential when experiments are repeated months apart or replicated across sites.
Presentation and consistency. Uniform fill, intact lyophilized cake appearance, seal integrity, and consistent labeling across shipments are practical proxies for process control.

Some laboratories add functional confirmation — a receptor phosphorylation or cell proliferation readout — since analytical purity does not by itself establish that a protein is correctly folded and bioactive.

Where the Open Questions Are

The honest summary is that IGF-1 LR3 is well characterized as a reagent and thinly characterized as a biological intervention. Several gaps stand out.

Effect direction is context-dependent. The fetal sheep growth-restriction work reporting no growth promotion sits uneasily beside guinea pig data reporting organ growth. Understanding which physiological contexts produce which response is unresolved.
Systemic feedback is under-mapped. Suppression of endogenous IGF-I, IGF-II, and binding proteins during infusion raises questions about net signaling that single-endpoint studies rarely address.
Structural change without functional change. The 5XFAD finding of plaque remodeling without cognitive preservation exemplifies a broader problem: which biomarkers, if any, track meaningful outcomes.
Metabolic crosstalk. The extent of insulin receptor engagement and its consequences for glucose regulation across models remains incompletely defined.
Human data are absent. There is no controlled clinical literature supporting the performance or body-composition uses often discussed informally, and this page makes no claims about them.

For researchers building a protocol, that combination — a clear mechanism, a modest and mixed evidence base, and rigorous material characterization — is the realistic starting point.

Research-grade IGF-1 LR3: Real Peptides supplies IGF-1 LR3 for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore IGF-1 LR3 research on Real Peptides

The articles below go deeper on the questions researchers ask most about IGF-1 LR3.

Buying & quality

Reconstitution, storage & handling

Stacks & comparisons

Legal & regulatory

Research timelines & mechanisms

How Long IGF-1 LR3 Stays in System — Clearance Timeline

Safety & side effects

Research questions

References

Peer-reviewed sources on IGF-1 LR3 indexed in PubMed, listed for research context. Real Peptides supplies IGF-1 LR3 for laboratory research use only.

IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American journal of physiology. Endocrinology and metabolism, 2025. PMID 39679943. doi:10.1152/ajpendo.00259.2024
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer's disease : JAD, 2025. PMID 39610283. doi:10.1177/13872877241299056
Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied microbiology and biotechnology, 2023. PMID 37261455. doi:10.1007/s00253-023-12606-0
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of developmental origins of health and disease, 2023. PMID 37114757. doi:10.1017/S2040174423000090
Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. The Journal of endocrinology, 1995. PMID 7561636. doi:10.1677/joe.0.1460247

Questions

Native IGF-1 is 70 amino acids. IGF-1 LR3 is 83 residues: it carries an arginine substitution replacing glutamic acid at position 3 and a 13-amino-acid N-terminal extension peptide. Both modifications sharply reduce affinity for IGF binding proteins, which is the functional basis for the analog's greater persistence in cell culture and in preclinical models compared with the native peptide.

Cultured cells secrete IGF binding proteins into the medium, which sequester native IGF-1 and blunt its signaling. Because IGF-1 LR3 binds those proteins poorly, a larger free fraction remains available to engage the type 1 IGF receptor. This makes it effective at lower concentrations in serum-free and low-serum media, which is its longest-established and best-documented laboratory application.

No. IGF-1 LR3 is not an FDA-approved drug for any of the applications discussed here, is not a dietary supplement, and has not been authorized as a therapeutic product. It is supplied for laboratory research use only, to qualified researchers and institutions, and is not intended for human or veterinary use. Researchers should also note it appears on anti-doping prohibited lists.

Results are mixed. A 2025 fetal sheep study reported no growth promotion in late-gestation growth-restricted fetuses. A 1995 guinea pig study reported organ growth alongside reduced circulating IGF and binding protein concentrations. A 2025 mouse study reported cortical amyloid plaque remodeling without cognitive preservation. Evidence remains preliminary and context-dependent rather than uniformly supporting anabolic effects.

At minimum, a batch-specific certificate of analysis from an independent laboratory, reversed-phase HPLC data showing purity and related-substance peaks, and mass spectrometry confirming observed mass matches the calculated mass for the 83-residue construct. A traceable lot number linking vial to COA matters for reproducibility. Some laboratories add a functional bioassay, since purity alone does not confirm correct folding.

Recombinant proteins of this size degrade considerably faster in solution than in dry form, through hydrolysis, oxidation, and aggregation. Lyophilization removes water and stabilizes the material for shipping and long-term frozen storage. Once reconstituted, stability declines, which is why laboratories typically aliquot immediately into single-use volumes and document reconstitution date, diluent, and concentration on each aliquot.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA